Agios Pharmaceuticals, Inc.
AGIOAgios Pharmaceuticals, Inc. is a biotechnology company focused on developing targeted therapies for cancer and rare genetic metabolic disorders. Founded in 2007 and based in Cambridge, Massachusetts, Agios specializes in precision medicine strategies, aiming to improve outcomes for patients through innovative small-molecule drugs. The company's portfolio includes treatments targeting metabolic pathways fundamental to cancer cell growth and survival.
Company News
The sickle cell disease market is projected to grow at a 22.1% CAGR by 2034, driven by increasing disease prevalence, awareness, and advancements in gene therapies, with emerging treatments from multiple pharmaceutical companies.
Agios Pharmaceuticals' stock dropped nearly 50% after mixed Phase 3 trial results for its sickle cell disease drug mitapavit. The drug met one primary endpoint of hemoglobin response but failed to significantly reduce sickle cell pain crises.
Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
A Wall Street analyst who was an early proponent of GenAI says investors are facing a "trough of disillusionment," surrounding Nvidia, other companies.
